ASLAN Pharmaceuticals Q4 EPS $(0.16) Down From $(0.15) YoY
ASLAN Pharmaceuticals (NASDAQ:ASLN) reported quarterly losses of $(0.16) per share. This is a 6.67 percent decrease over losses of $(0.15) per share from the same period last year.
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.
ASLAN Pharma Kickstarts Mid-Stage Atopic Dermatitis Trial, Data Expected In 2023
ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has
The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference.
